Hongwei Yue

Hongwei Yue

Auto-generated profile, based on publicly available information

Hongwei Yue

Qilu Hospital of Shandong University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
HYHuaqing Ye
Huaqing Ye
HYHongwei Yue
Hongwei Yue
SWShujian Wei
Shujian Wei
KWKaiyi Wang
Kaiyi Wang
KYKehui Yang
Kehui Yang
YCYuguo Chen
Yuguo Chen
Background: The inactivating ALDH2 rs671 polymorphism, present in ≈8% of the global population and up to 30% to 50% of East Asian individuals, has been negatively associated with hypertension. However, the direct role of ALDH2 (aldehyde dehydrogenase 2) dysfunction in this association, as well as the underlying mechanisms by which ALDH2 rs671 influences blood pressure regulation, remains unclear. Methods: Using Aldh2 E506K (equivalent to the human ALDH2 rs671 polymorphism), Aldh2 global knockout, and endothelial cell‐specific Aldh2 knockout mice, we assessed changes in blood pressure (BP) using both telemetry and tail‐cuff methods. Mass spectrometry, coimmunoprecipitation, and other biological techniques were used to elucidate underlying molecular mechanisms. Results: Aldh2 E506K or Aldh2 global knockout mice displayed a significant decrease in BP under both physiological conditions and angiotensin II–induced hypertension, independent of changes in cardiac output and renal function. Mechanistic studies revealed that endothelial ALDH2 dysfunction inhibited the lysosomal degradation of PIEZO1 (piezo‐type mechanosensitive ion channel component 1), resulting in its upregulated protein level and activation of the PIEZO1–endothelial nitric oxide synthase BP regulatory axis. PIEZO1 knockdown or channel inhibition by Grammostola spatulata mechanotoxin 4 peptide reversed the reduced BP phenotype exhibited by Aldh2 ECKO mice. Using coimmunoprecipitation combined with mass spectrometry, the molecular chaperone HSPA5 (heat shock protein family A member 5) was identified as a novel interactor with PIEZO1, binding to its C‐terminus. HSPA5, induced by aldehyde accumulation, functionally enhanced PIEZO1 protein stability upon ALDH2 loss‐of‐function mutation. Endothelial‐specific overexpression of HSPA5 could alleviate angiotensin II–induced hypertension in mice. Conclusions: Our study provides definitive experimental evidence that ALDH2 rs671 variation or endothelial Aldh2 deficiency plays a protective role in BP regulation by activating the HSPA5–PIEZO1–endothelial nitric oxide synthase axis. We also revealed the previously unrecognized role of HSPA5 in maintaining PIEZO1 stability and BP regulation, providing a potential novel intervention target for hypertension therapy.

24 March 2026 in Circulation
Verified
Journal Article
Open access
SSSong Sun
Song Sun
XZXuan Zhang
Xuan Zhang
HYHongwei Yue
Hongwei Yue
CFCuiqin Fan
Cuiqin Fan
YZYi Zhang
Yi Zhang
YCYuguo Chen
Yuguo Chen
BACKGROUND: Acute myocardial infarction (AMI) caused by thrombosis is a major cause of mortality. A polymorphism in Aldh2 gene (rs671) is found in approximately 30% to 50% of East Asians, and it is a risk factor for AMI. This mutation impairs aldehyde dehydrogenase 2 (ALDH2) function, but the effect of ALDH2 on platelet activation and thrombosis is unknown. METHODS: Platelets were isolated from platelet-specific Aldh2 knockout ( Aldh2 -/- ) and ALDH2 E506K knock-in mice (which corresponds to human Aldh2 rs671 gene mutation), as well as from healthy human donors with the Aldh2 rs671. Arterial thrombosis was measured in a FeCl 3 -induced thrombosis mouse model. The efficacy of Alda-1, an ALDH2 activator, in mitigating thrombogenesis was measured in ALDH2 E506K mice. Using a murine model of myocardial infarction (MI) model, we analyzed the effects of platelet Aldh2 on micro-thrombosis and infarct expansion post-MI. In addition, we enrolled 118 patients of different Aldh2 rs671 genotypes (GG, GA, and AA) diagnosed with ST elevation myocardial infarction (STEMI) to analyze the association between rs671 genotype and platelet activation and thrombosis. RESULTS: Platelets from Aldh 2 -/- and ALDH2 E506K mice showed enhanced agonist induced aggregation, ATP release, integrin αIIbβ3 activation, P-selectin release, spreading, and clot retraction. Human platelets with the Aldh2 rs671 variant also exhibited increased activation. Mutation of Aldh2 or platelet-specific knockout of Aldh2 exacerbated thrombus formation in a mouse model of thrombosis. The ALDH2 activator, Alda-1, reduced thrombosis in ALDH2 E506K mice. We explored pathways mediating the effect of Aldh2 on platelet activation. We found that platelets lacking Aldh2 produced more reactive oxygen species (ROS) and less nitric oxide (NO) than wild-type platelets. Furthermore, platelets lacking Aldh2 are also more susceptible to activation by aldehydes. Additionally, platelets from mice lacking Aldh2 had increased elevated mitophagy and hyperactivity. ACAD10 mediated some of the effects of ALDH2 on mitophagy. Mice lacking Aldh2 had increased micro-thrombosis and myocardial infarct expansion. Finally, elevated platelet activation and thrombus markers were also observed in plasma from patients with STEMI patients who had the rs671 variant. CONCLUSIONS: The Aldh2 rs671 variant, which impairs ALDH2 function, increases platelet activation and thrombus formation in vivo through aldehyde accumulation and ROS buildup. Abnormal ACAD10 homeostasis might also contribute to this hyperactivity via enhancing platelet mitophagy. Our findings suggest the potential of ALDH2 as a novel antiplatelet target. Future studies are needed to explore the effects of more aggressive antiplatelet therapy for patients at risk of MI who carry the Aldh2 rs671 mutation.

14 October 2022 in Research Square
Verified
Preprint
Open access
PDF file
NLNa Liu
Na Liu
JZJing Zhang
Jing Zhang
WDWenqi Duan
Wenqi Duan
TLTingting Luo
Tingting Luo
CWCong Wu
Cong Wu
DGDi Ge
Di Ge
Background Siegesbeckia orientalis L. have been used as a traditional Chinese medicine “Xi-Xian-Cao” for centuries with multiple medicinal benefits including cancerous treatment. Breast cancer is one of the leading causes of death in women worldwide. And the Triple-negative breast cancer (TNBC), accounting for about 15 ~ 18% of all breast cancers, is notorious for its poor prognosis, high rate of relapse and short overall survival. Because of lacking effective therapeutic targets or drugs, treatment of TNBC in clinical encounters great obstacle. Recently, we have reported the isolation of twenty-seven germacranolides including So-2 from the aerial parts of S. orientalis with potent cytotoxicity against breast cancer cells. However, the specific mechanism needs to be elucidated. The aim of this study is to verified the anti-tumor function of the natural compound So-2 and uncover the underlying mechanism. Methods We investigated the anti-tumor role of So-2 both in vitro and in vivo. An orthotopic transplantation tumor model was established to assess the in vivo antitumor effects of So-2. Two TNBC cell lines MDA-MB-231 and BT-549 cells were employed to study the cytotoxicity effect and specific mechanism of So-2 in vitro. We studied the influence of So-2 on TNBC cell proliferation, migration and ferroptosis in detail. Results So-2 was shown to cause cell cycle arrest and suppress TNBC cell proliferation and migration. Also, So-2 was identified to be a bona fide ferroptosis inducer in TNBC cells. We also characterized the oncogenic role of the transcription factor E2F7 in TNBC. And E2F7 was downregulated by So-2 while inducing ferroptosis. E2F7 was demonstrated to be involved in the ferroptosis-inducing and tumor suppression effect of So-2. Conclusion So-2 exhibits inhibitory effect on TNBC growth and migration both in vitro and vivo by inducing TNBC ferroptosis via downregulating the expression of E2F7. These findings provide valuable insight into the pathogenesis of TNBC. The natural compound So-2, isolated from Chinese traditional medicine, might be a prospective drug candidate in TNBC therapy.